Process for the preparation of 2′-fluoro-5-methyl-&bgr;-L-arabinofuranosyluridine
    31.
    发明授权
    Process for the preparation of 2′-fluoro-5-methyl-&bgr;-L-arabinofuranosyluridine 失效
    2'-氟-5-甲基-β-L-阿拉伯呋喃糖基尿苷的制备方法

    公开(公告)号:US06512107B2

    公开(公告)日:2003-01-28

    申请号:US09121294

    申请日:1998-07-23

    IPC分类号: C07H1919

    CPC分类号: C07H9/04 C07H3/02 C07H19/06

    摘要: The present invention relates to a novel and improved process for preparing 2′-fluoro-5-methyl-&bgr;-L-arabinofuranosyluridine represented by formula (I) which shows anti-viral activity, especially potent anti-viral activity against hepatitis B-virus and Epstein-Barr virus:

    摘要翻译: 本发明涉及一种制备式(I)表示的2'-氟-5-甲基-β-L-阿拉伯呋喃糖基尿苷的新型改进方法,该方法显示出抗病毒活性,特别是抗乙型肝炎病毒的抗病毒活性 和爱泼斯坦 - 巴尔病毒:

    Prodrug azide compositions and compounds
    35.
    发明授权
    Prodrug azide compositions and compounds 失效
    前药叠氮组合物和化合物

    公开(公告)号:US06271212B1

    公开(公告)日:2001-08-07

    申请号:US09033996

    申请日:1998-03-03

    IPC分类号: A61K3170

    摘要: Pharmaceutical prodrug compositions are provided comprising azide derivatives of drugs which are capable of being converted to the drug in vivo. Azide derivatives of drugs having amine, ketone and hydroxy substituents are converted in vivo to the corresponding drugs, increasing the half-life of the drugs. In addition azide prodrugs are often better able to penetrate the blood-brain barrier than the corresponding drugs. Especially useful are azide derivatives of cordycepin, 2′-F-ara-ddI, AraA, acyclovir, penciclovir and related drugs. Useful azide prodrugs are azide derivatives of therapeutic alicyclic amines, ketones, and hydroxy-substituted compounds, including aralkyl, heterocyclic aralkyl, and cyclic aliphatic compounds, where the amine or oxygen moiety is on the ring, or where the amine or oxygen moiety is on an aliphatic side chain, as well as therapeutic purines and pyrimidines, nucleoside analogs and phosphorylated nucleoside analogs.

    摘要翻译: 提供药物前药组合物,其包含能够在体内转化为药物的药物的叠氮衍生物。 具有胺,酮和羟基取代基的药物的叠氮衍生物在体内转化为相应的药物,增加药物的半衰期。 此外叠氮化物前药通常比相应的药物更好地穿透血脑屏障。 特别有用的是虫草素,2'-F-ara-ddI,AraA,阿昔洛韦,喷昔洛韦和相关药物的叠氮衍生物。 有用的叠氮化物前药是治疗脂环族胺,酮和羟基取代的化合物的叠氮化物衍生物,包括芳烷基,杂环芳烷基和环状脂族化合物,其中胺或氧部分在环上,或胺或氧部分在其上 脂肪族侧链,以及治疗性嘌呤和嘧啶,核苷类似物和磷酸化核苷类似物。

    Syntheses of acyclic guanine nucleosides
    36.
    发明授权
    Syntheses of acyclic guanine nucleosides 失效
    无环鸟嘌呤核苷的合成

    公开(公告)号:US5583225A

    公开(公告)日:1996-12-10

    申请号:US245024

    申请日:1994-05-17

    申请人: Chung K. Chu Jinfa Du

    发明人: Chung K. Chu Jinfa Du

    IPC分类号: C07D473/00 C07D473/18

    CPC分类号: C07D473/00

    摘要: A method is provided for the synthesis of synthesis of acyclic purine nucleosides, particularly 9-(2-hydroxyethoxymethyl)-guanine (acyclovir) and 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine ("DHPG") where the N.sup.2,N.sup.9 -diprotected guanine is reacted with CH.sub.3 C(O)OCH.sub.2 O(CH.sub.2).sub.2)OC(O)CH.sub.3 or diacetoxypropane, respectively, in the presence of a mixture of an acid and acetic anhydride, or in the presence of an acid, where the acid can be phosphoric acid or polyphosphoric acid.

    摘要翻译: 提供了合成无环嘌呤核苷,特别是9-(2-羟基乙氧基甲基)鸟嘌呤(无环鸟苷)和9 - [(1,3-二羟基-2-丙氧基)甲基]鸟嘌呤(“DHPG”)的合成方法。 其中在酸和乙酸酐的混合物存在下,或者在存在下,将N 2,N 9 - 二保护的鸟嘌呤分别与CH 3 C(O)OCH 2 O(CH 2)2)OC(O)CH 3或二乙酰氧基丙烷反应 酸,其中酸可以是磷酸或多磷酸。